AI Science Tracker

DeepSomatic: a neural network for somatic variants in tumors

Google Research · 16 Oct 2025 · medicine

Discovery

Google Research

DeepSomatic: a neural network for somatic variants in tumors

For insertions and deletions, it reaches 90% with Illumina data versus 80% for the best other tool, and over 80% with PacBio versus under 50%. In eight pediatric leukemia samples, it recovered known variants and flagged ten new ones that have not been independently validated. The tool and CASTLE dataset are open.

Technology: DeepSomatic (convolutional neural network)

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: DeepSomatic was benchmarked against SomaticSniper, MuTect2, Strelka2 and ClairS on the CASTLE cell-line dataset with held-out chromosomes and genomes, across Illumina, PacBio and other platforms.
  • Still unknown: The benchmark uses research cell lines rather than patient tumors, the glioblastoma result rests on one sample, and the 10 new leukemia variants are not stated to be validated.
  • AI role: A convolutional neural network applied to sequencing data converted to images separated germline, somatic and error signals to call tumor variants.

Evidence sources: https://research.google/blog/using-ai-to-identify-genetic-variants-in-tumors-with-deepsomatic/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41587-025-02839-x&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: blog. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 59 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.